The Andrews Labor Government is backing Victorian research into new coronavirus treatment, including a nasal spray medication that envelops the virus and reduces household transmission.
Acting Minister for Innovation, Medical Research and the Digital Economy Mary-Anne Thomas today announced $13.3 million in grants for seven research projects examining a range of coronavirus treatment options.
University of Melbourne and Monash University have received $4.2 million to establish a six-month clinical trial, developed in collaboration with Oxford University, of a heparin-based nasal spray to be used in households where a person has coronavirus.
The second most widely used drug in the world and primarily prescribed as a blood-thinner to treat or prevent blood clots, heparin forms the base of the nasal spray treatment which is already being hailed as a success for its easy administration, stability at room temperature and global availability.
The IntraNasal HEpaRin Trial (INHERIT) will be led by the Northern Hospital, using the Covid (Oximetry) Monitoring and Early Treatment (COMET) platform that has enabled researchers to access and treat patients within 24 hours of their diagnosis, speeding up treatment and providing remote patient monitoring through portable oximeter devices that measure oxygen levels in blood.
Other research projects receiving funding include $2 million for a Walter and Eliza Hall Institute trial of antiviral cocktails for immunocompromised patients unable to receive coronavirus vaccines, and $1.8 million for a Burnet Institute study on a suite of biological medications that could neutralise and kill virus-infected cells. For the full list, go to djpr.vic.gov.au/medical-
In the past year, the Labor Government has invested more than $590 million in medical research—including up to $400 million for a new Australian Institute of Infectious Disease to lead the fight against future pandemics. Clinical trials held in Victoria contribute more than $300 million annually to the state’s economy.
Last week, Victorian scientists and manufacturers reached a major milestone, unveiling Australia’s first mRNA COVID-19 vaccine candidate after a research period of just five months. Clinical trials will commence in early 2022.
Follow The Indian Sun on Twitter | Instagram | Facebook
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
